Interferon-lambda (IFN-λ) induces signal transduction and gene expression in human hepatocytes, but not in lymphocytes or monocytes
Open Access
- 20 December 2012
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 93 (3) , 377-385
Abstract
Interferon-alpha and interferon-lambda induce distinct functional responses in human hepatocytes, lymphocytes, and monocytes. This study compared the ability of IFN-α and IFN-λ to induce signal transduction and gene expression in primary human hepatocytes, PBLs, and monocytes. IFN-α drug products are widely used to treat chronic HCV infection; however, IFN-α therapy often induces hematologic toxicities as a result of the broad expression of IFNARs on many cell types, including most leukocytes. rIFN-λ1 is currently being tested as a potential alternative to IFN-α for treating chronic HCV. Although IFN-λ has been shown to be active on hepatoma cell lines, such as HepG2 and Huh-7, its ability to induce responses in primary human hepatocytes or leukocytes has not been examined. We found that IFN-λ induces activation of Jak/STAT signaling in mouse and human hepatocytes, and the ability of IFN-λ to induce STAT activation correlates with induction of numerous ISGs. Although the magnitude of ISG expression induced by IFN-λ in hepatocytes was generally lower than that induced by IFN-α, the repertoire of regulated genes was quite similar. Our findings demonstrate that although IFN-α and IFN-λ signal through distinct receptors, they induce expression of a common set of ISGs in hepatocytes. However, unlike IFN-α, IFN-λ did not induce STAT activation or ISG expression by purified lymphocytes or monocytes. This important functional difference may provide a clinical advantage for IFN-λ as a treatment for chronic HCV infection, as it is less likely to induce the leukopenias that are often associated with IFN-α therapy.Keywords
Funding Information
- U.S. Food and Drug Administration, Center for Drug Evaluation and Research
- U.S. National Institutes of Health
This publication has 42 references indexed in Scilit:
- Interferon-lambda and therapy for chronic hepatitis C virus infectionTrends in Immunology, 2011
- IL28B inhibits hepatitis C virus replication through the JAK–STAT pathwayJournal of Hepatology, 2011
- USP18-Based Negative Feedback Control Is Induced by Type I and Type III Interferons and Specifically Inactivates Interferon α ResponsePLOS ONE, 2011
- A diverse range of gene products are effectors of the type I interferon antiviral responseNature, 2011
- Comparative Analysis of the Lambda-Interferons IL-28A and IL-29 regarding Their Transcriptome and Their Antiviral Properties against Hepatitis C VirusPLOS ONE, 2010
- Differential Transcriptional Responses to Interferon-α and Interferon-γ in Primary Human HepatocytesJournal of Interferon & Cytokine Research, 2010
- Interferon-inducible antiviral effectorsNature Reviews Immunology, 2008
- IFN-Lambda (IFN-λ) Is Expressed in a Tissue-Dependent Fashion and Primarily Acts on Epithelial Cells In VivoPLOS Pathogens, 2008
- Type III Interferon (IFN) Induces a Type I IFN-Like Response in a Restricted Subset of Cells through Signaling Pathways Involving both the Jak-STAT Pathway and the Mitogen-Activated Protein KinasesJournal of Virology, 2007
- Lambda Interferon (IFN-λ), a Type III IFN, Is Induced by Viruses and IFNs and Displays Potent Antiviral Activity against Select Virus Infections In VivoJournal of Virology, 2006